Skip to Content

Tag: IPO


Also Noted

AdaptHealth merger finalized, stock goes live

November 12, 2019HME News Staff

NEW YORK and PLYMOUTH MEETING, Pa. - DFB Healthcare Acquisitions Corp. has closed on its merger with AdaptHealth Holdings. The combined company, which has been renamed AdaptHealth Corp., expected its Class A common stock and public warrants to list on the Nasdaq Capital Market under the new trading symbols AHCO and AHCOW, respectively, on Nov. 11. “(CEO Luke McGee) and his team have built one of the industry's leading HME providers through a combination of accretive capital deployment; high-touch...

AdaptHealth, DFB, IPO, M&A


Read Full Articlered right arrow icon

Guest Blog

The implications of AdaptHealth's upcoming IPO

October 1, 2019Bradley Smith

When AdaptHealth's plan to become a public company was announced in July, ears perked up throughout the HME industry. New IPO listings by DME providers are rare. That could change following Adapt's IPO. To recap, Adapt will combine with DFB Healthcare Acquisitions Corp., which is currently traded on the NASDAQ under symbols DFBH and DFBHW. Once the combination of companies is completed, it is expected that DFB will change its name to AdaptHealth Holding Corp. and remain listed on the NASDAQ under...

AdaptHealth, Bradley Smith, IPO, M&A, Vertess


Read Full Articlered right arrow icon

Also Noted

Inspire Medical Systems sets terms for IPO

April 24, 2018HME News Staff

MINNEAPOLIS ≠- Inspire Medical Systems plans to raise $75 million by offering 5 million shares at a price range of $14 to $16 as part of an initial public offering that it announced earlier this month. Insiders plan to purchase $15 million worth of shares in the IPO, according to Nasdaq. Inspire Medical Systems, which plans to list on the New York Stock Exchange under the symbol INSP, makes FDA-approved neurostimulation technology that provides treatment for moderate to severe obstructive sleep...

Inspire Medical Systems, IPO, sleep apnea


Read Full Articlered right arrow icon

Also Noted

Maker of CPAP alternative to go public

April 10, 2018HME News Staff

MINNEAPOLIS - Inspire Medical Systems, the maker of FDA-approved neurostimulation technology that provides treatment for moderate to severe OSA, has filed paperwork for an initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Inspire has applied to list its common stock on the New York Stock Exchange under the ticker symbol “INSP.” BofA Merrill Lynch and Goldman Sachs & Co. LLC are serving as...

CPAP alternative, Inspire Medical Systems, IPO


Read Full Articlered right arrow icon

Also Noted

Ottobock draws PE interest

February 1, 2017HME News Staff

DUDERSTADT, Germany - Ottobock has attracted interest from private equity firms, including KKR and CVC, according to Reuters. The firms are looking for a 20% stake in the company core business of making artificial limbs. Ottobock is also drawing interest from buyout firms BC Partners and Advent. The company is targeting PE firms, affluent families and technology funds as potential buyers in a deal it hopes to complete by the end of June, ahead of a planned initial public offering, Reuters reported....

IPO, M&A, o&P, Ottobock, private equity


Read Full Articlered right arrow icon

Also Noted

ConvaTec hits London market with $1.8B IPO

October 27, 2016HME News Staff

LONDON - ConvaTec on Wednesday raised nearly $1.8 billion in London's biggest initial public offering of 2016, according to news reports. The company, which manufactures ostomy, wound, skin, continence and other critical care products, will use the proceeds from the IPO to redeem or repay debt. ConvaTec's shares traded just below their offer price of $2.76, at $2.75. The IPO represents about 33.8% of the company's stock, assuming no exercise of an overallotment option, and will rise to 38.9% if the...

ConvaTec, IPO


Read Full Articlered right arrow icon

Also Noted

Inogen sets IPO terms

February 6, 2014HME News Staff

GOLETA, Calif. - Inogen hopes to raise $75 million in its IPO by offering 4.4 million shares—20% insider—at $16 to $18 per share, according to news reports. At the midpoint of its proposed price range, its fully diluted market value would be $342 million, Renaissance Capital reports. For the 12 months ended Sept. 30, 2013, the portable oxygen concentrator manufacturer/provider reported $70 million in sales. Inogen filed for the IPO in November. It plans to trade on the NASDAQ under the...

Inogen, IPO


Read Full Articlered right arrow icon

Vendors

Inogen details strengths in bid to court investors

December 6, 2013Liz Beaulieu, Editor

GOLETA, Calif. - Inogen's Nov. 27 filing for a proposed initial public offering (IPO) provides a window into the inner workings of the company, including its direct-to-consumer strategy and its financial viability.Inogen lists its direct-to-consumer strategy as one of its main strengths, setting it apart from other HME manufacturers and helping it to grow revenue from $10.7 million in 2009 to $48.6 million in 2012. The company adopted the strategy in 2009, after receiving pushback from HME providers...

competitive bidding, Inogen, IPO


Read Full Articlered right arrow icon

Also Noted

Inogen files for IPO

December 2, 2013HME News Staff

GOLETA, Calif. - Inogen has registered with the Securities and Exchange Commission, proposing an initial public offering of common stock, according to a Nov. 27 news release. The company has not yet determined the number of shares it will offer, or the price range but is seeking to raise up to $86 million. Private equity firm Novo A/S in 2012 invested $22 million in Inogen. J.P. Morgan is the lead bookrunner, Leerick Swann is lead manager and William Blair and Stifel are co-managers, according...

Inogen, IPO


Read Full Articlered right arrow icon